Clever combo: multi-modality imaging developed by novel optics


Funding novel optics and imaging software encourages the evolution of multi-modality imaging and provides more business opportunities.

Funding novel optics and imaging software encourages the evolution of multi-modality imaging and provides more business opportunities, according to the latest analysis from Frost and Sullivan.

The publication, "Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging (Technical Insights)", demonstrates that the development of novel optics, data acquisition methods and image processing software has significantly encouraged the evolution of optical imaging technologies.

Optical imaging, at both macroscopic and microscopic levels, are frequently used by clinicians to image tissues with enhanced contrast and resolution capabilities.

Prasanna Vadhana Kannan, Senior Research Analyst at Technical Insights, said, "Technology trends are moving from conventional confocal microscopy to optical coherence tomography (OCT), with the adoption of newer technologies such as adaptive optics and polarization imaging in ophthalmology. Several start-ups are developing innovative technologies, most of which are in the near completion and advanced phases of clinical approval in the optical imaging market."

Kannan continued, "OCT is truly an easy-to-use modality that provides digital cellular 2-D and 3-D imaging solutions for clinical and research pathology lab application needs on fixed or fresh tissue. Further refinement could result in achieving significantly higher resolution capabilities and better differentiation of cancerous lesions, embryology studies, and stem cells (involving therapeutics research)."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.